Value Peer-spectives

Rapid Adoption of Oncology Drugs Improves Survival

Chase Doyle

December 2017, Vol 8, No 5 - Value in Oncology

Innovation takes time, especially when it comes to cancer research. However, delays in the adoption of novel oncology treatments can have a significant impact on patient health, reported Jason Shafrin, PhD, Director of Healthcare Quality and Value-Based Research Methods, and Senior Research Economist, Precision Health Economics, Los Angeles, CA, who presented the results of a geographic-based analysis of claims data at the 2017 Cancer Survivorship Symposium. [ Read More ]

Identifying Correct Molecular Target Essential for Treating Non–Small-Cell Lung Cancer

Wayne Kuznar

December 2017, Vol 8, No 5 - Value in Oncology

Orlando, FL—Non–small-cell lung cancer (NSCLC) comprises several different subtypes, necessitating broad molecular panel testing to understand the correct diagnosis and the appropriate treatment, said Wallace Akerley, MD, Senior Director, Community Oncology Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference. [ Read More ]

ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year

Eileen Koutnik-Fotopoulos

June 2017, Vol 8, No 3 - Value in Oncology

Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. This surge of progress using cancer immunotherapy has led the American Society of Clinical Oncology (ASCO) to name “Immunotherapy 2.0” as its cancer advance of the year for a second year in a row. [ Read More ]

Drug Costs, and Employers as Purchasers of Care

F. Randy Vogenberg, PhD, RPh, FASHP

April 2017, Vol 8, No 2 - Employers’ Perspective

Unlike other countries around the world, the United States does not regulate or negotiate drug prices. In general, the European Union members (eg, United Kingdom, France, Germany), Australia, and other countries incorporate pricing at the time of new drug approval, and allow the use of a new drug when it provides a significant clinical benefit over existing drugs, relative to the drug price. [ Read More ]

Comparing the Current Value Frameworks in Oncology

Meg Barbor, MPH

April 2017, Vol 8, No 2 - Value in Oncology

Chicago, IL—Escalating drug prices have put value frameworks in the spotlight, and the identification of the key questions and the audience addressed in each value framework is vital to understanding the value landscape, said Kasia Shields, PharmD, MBA, BCOP, BCPS, Director, Medical Communications, Xcenda/AmerisourceBergen, at the 2016 Hematology/Oncology Pharmacy Association Oncology Pharmacy Practice Management Program. [ Read More ]

How Washington Is Shaping a New Healthcare Reform

Gail Thompson

April 2017, Vol 8, No 2 - Value in Oncology

Former Senator Bill Frist, MD, opened the 2017 Cancer Center Business Summit in Las Vegas, NV, in early February, with a smile and a warning that we are in unfamiliar territory as the new Congress and the new administration move into 2017, territory that may occur only 2 or 3 times in a century. He said that, “For the first time since 1929, the GOP [the Republican Party] controls Congress, the White House, most governorships and state houses, as well as the Supreme Court.” [ Read More ]

Leveraging Financial Advocates to Improve Patient Care

Meg Barbor, MPH

April 2017, Vol 8, No 2 - Value in Oncology

St Louis, MO—Financial counselors can help patients find assistance with the often-prohibitive costs of cancer treatment. According to Jordan Karwedsky, a financial counselor at HSHS St Vincent Regional Cancer Center and Green Bay Oncology, Green Bay, WI, patients at these organizations saved more than $1 million on intravenous and oral chemotherapy in 2015 through copay assistance. [ Read More ]

Shifting Targets for Providers, Payers, and Patients with Cancer: Perspectives in Healthcare Reform

Gail Thompson

April 2017, Vol 8, No 2 - Value in Oncology

Las Vegas, NV—A panel discussion at the 2017 Cancer Center Business Summit revealed continuing gaps in the evolution of healthcare reform among providers, payers, and patients with cancer. Michael Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, New York, NY—an oncologist with experience on the provider and the payer sides—moderated the panel discussion, which offered perspectives from the trenches on healthcare reform. [ Read More ]

Health Plans Must Monitor the Oncology Pipeline to Apply Appropriate Coverage Criteria, Maintain Treatment Value

James T. Kenney Jr, RPh, MBA

February 2017, Vol 8, No 1 - Payer's Perspective

The 2016 American Society of Hematology (ASH) meeting provided insight into new treatment options and mechanism of action choices for hematologic cancers. Health plans need to continue to expand their knowledge and expertise in all cancer types to maintain the ability to manage and apply coverage criteria appropriately as FDA approvals continue to increase in oncology. [ Read More ]